Results 131 to 140 of about 124,738 (260)

In vitro comparison of the susceptibilities of the same drug resistance mutations to reverse-transcriptase inhibitors of subtype B and CRF01_AE HIV-1 strains. [PDF]

Sci Rep
Li H, Shen K, Han J, Liu Y, Zhang L, Liu X, Jia L, Zhang B, Wang X, Li J, Dai E, Yan H, Li L.   +12 more
europepmc   +1 more source

The Influence of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial Activity, Lipid Content, and Fatty-Acid-Binding Protein Levels in Microglial HMC3 Cells. [PDF]

Pharmaceuticals (Basel), 2023
Lipke K, Kubis-Kubiak A, Piwowar A.
europepmc   +1 more source

Multi‐Cohort Analysis Reveals Genetic Predispositions to Clonal Hematopoiesis as Mutation‐Specific Risk Factors for Stroke

Advanced Genetics, Volume 6, Issue 1, March 2025.
This study comprehensively evaluated the differential effect of clonal hematopoiesis (CH) mutations on the risk of various stroke subtypes and functional recovery. It shows that TET2 is associated with small vessel stroke possibly via a pro‐inflammatory pathway. Abstract Recent observational studies have found an association between Clonal Hematopoesis
Shuyang Lin, Yang E. Li, Yan Wang
wiley   +1 more source

Reverse transcriptase inhibitors in Aicardi-Goutières syndrome: A crossover clinical trial. [PDF]

Dev Med Child Neurol
Crow YJ, Briggs TA, Eleftheriou D, Parida A, Battison C, Giddings A, Kennel T, Parker RA, AGS‐RTIs Study Group.   +8 more
europepmc   +1 more source

Design, Synthesis, and Biological Activity of Amine-Type Cyclopentanepyridinone Derivatives as HIV‑1 Non-Nucleoside Reverse Transcriptase Inhibitors. [PDF]

ACS Omega
Castro-Perea NV, Rodríguez-Vega G, Abarca-Magaña JC, Ruiz-Rivera MB, Medina-Franco JL, Huerta L, Chávez D.   +6 more
europepmc   +1 more source

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors. [PDF]

Commun Chem, 2023
Jiang X, Huang B, Rumrill S, Pople D, Zalloum WA, Kang D, Zhao F, Ji X, Gao Z, Hu L, Wang Z, Xie M, De Clercq E, Ruiz FX, Arnold E, Pannecouque C, Liu X, Zhan P.   +17 more
europepmc   +1 more source

Erratum: Author correction to 'Approved HIV reverse transcriptase inhibitors in the past decade' [Acta Pharmaceutica Sinica B 12 (2022) 1567-1590]. [PDF]

Acta Pharm Sin B, 2023
Li G, Wang Y, De Clercq E.
europepmc   +1 more source

Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles. [PDF]

Sci Adv
Wang Z, Rumrill S, Kang D, Guma SD, Feng D, De Clercq E, Pannecouque C, Chen CH, Arnold E, Ruiz FX, Liu X, Zhan P.   +11 more
europepmc   +1 more source

Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitors. [PDF]

Proc Natl Acad Sci U S A, 2022
Novototskaya-Vlasova KA, Neznanov NS, Molodtsov I, Hall BM, Commane M, Gleiberman AS, Murray J, Haber M, Norris MD, Leonova KI, Gudkov AV.   +10 more
europepmc   +1 more source

Prospects of Reverse Transcriptase Inhibitors [PDF]

, 2016
Chang Liu, Xiaohong Kong
openaire   +1 more source